58
Participants
Start Date
April 1, 2019
Primary Completion Date
November 30, 2019
Study Completion Date
December 31, 2019
Pregabalin 300mg
Group 1: will receive pregabalin as a monotherapy. Pregabalin will be administered according to the treatment recommendations for fibromyalgia in the package insert \[Pfizer Inc., 2012\] starting by 50 mg twice daily increasing to 300 mg twice daily according to the efficacy and tolerability for 3 months.
Combined pregabalin 300mg and milancipran 100mg
Group 2: will receive a combined pregabalin and milancipran. Pregabalin will be administered as group 1, while milancipran will be administered according to the treatment recommendations for fibromyalgia, starting by 50 mg once daily for 1 week then increased to reach 100 mg daily (50 mg twice daily) based on efficacy and tolerability for 3 month.
Alexandria University, Faculty of Medicine, Alexandria
Yousra Hisham Abdel Fattah
OTHER